Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Net revenues	$ 16,990	$ 15,423	$ 31,992	$ 28,766
Cost of products sold	4,291	4,346	8,509	8,348
Selling, general and administrative	3,632	3,253	7,210	6,546
Research and development	2,344	2,131	4,816	4,198
Acquired IPR&D and milestones	291	823	1,035	1,071
Other operating income	0	(24)	0	(24)
Total operating costs and expenses	10,558	10,529	21,570	20,139
Operating earnings	6,432	4,894	10,422	8,627
Interest expense, net	679	678	1,324	1,305
Other expense, net	1,475	2,662	3,781	4,107
Earnings before income tax expense	4,278	1,554	5,317	3,215
Income tax expense	662	613	1,004	985
Net earnings	3,616	941	4,313	2,230
Net earnings attributable to noncontrolling interest	3	3	5	6
Net earnings attributable to AbbVie Inc.	$ 3,613	$ 938	$ 4,308	$ 2,224
Per share data
Basic earnings per share (in dollars per share)	$ 2.04	$ 0.52	$ 2.42	$ 1.25
Diluted earnings per share (in dollars per share)	$ 2.03	$ 0.52	$ 2.42	$ 1.24
Weighted-average basic shares outstanding (in shares)	1,769	1,768	1,769	1,768
Weighted-average diluted shares outstanding (in shares)	1,771	1,771	1,773	1,772

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Statement of Cash Flows [Abstract]
Net earnings	$ 4,313	$ 2,230
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	382	367
Amortization of intangible assets	3,437	3,722
Deferred income taxes	(58)	(300)
Change in fair value of contingent consideration liabilities	3,905	4,313
Payments of contingent consideration liabilities	(1,784)	(1,408)
Stock-based compensation	610	589
Acquired IPR&D and milestones	1,035	1,071
Non-cash litigation reserve adjustments, net of cash payments	86	(750)
Other, net	(18)	96
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(1,282)	(1,496)
Inventories	(327)	(211)
Prepaid expenses and other assets	(338)	(257)
Accounts payable and other liabilities	(392)	(181)
Income tax assets and liabilities, net	(2,304)	(997)
Cash flows from operating activities	7,265	6,788
Cash flows from investing activities
Acquisitions of businesses, net of cash acquired	0	(204)
Other acquisitions and investments, net of cash acquired	(1,090)	(1,274)
Acquisitions of property and equipment	(587)	(504)
Other, net	(94)	66
Cash flows from investing activities	(1,771)	(1,916)
Cash flows from financing activities
Net change in commercial paper borrowings with original maturities of three months or less	(499)	1,549
Proceeds from issuance of other short-term borrowings	0	4,007
Repayments of other short-term borrowings	(2,000)	0
Proceeds from issuance of long-term debt	7,991	3,994
Repayments of long-term debt	(2,000)	(6,780)
Dividends paid	(6,156)	(5,835)
Purchases of treasury stock	(1,498)	(973)
Other, net	27	70
Cash flows from financing activities	(4,135)	(3,968)
Effect of exchange rate changes on cash and equivalents	(19)	39
Net change in cash and equivalents	1,340	943
Cash and equivalents, beginning of period	5,229	5,524
Cash and equivalents, end of period	$ 6,569	$ 6,467

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash and equivalents	$ 6,569	$ 5,229
Accounts receivable, net	13,824	12,589
Inventories	5,127	4,951
Prepaid expenses and other	8,149	6,293
Total current assets	33,669	29,062
Investments	266	268
Property and equipment, net	5,796	5,628
Intangible assets, net	49,139	52,641
Goodwill	35,519	35,640
Other assets	10,726	10,721
Total assets	135,115	133,960
Current liabilities
Short-term borrowings	0	2,499
Current portion of long-term debt	8,341	6,056
Accounts payable and accrued liabilities	33,301	34,734
Total current liabilities	41,642	43,289
Long-term debt	62,481	58,941
Deferred income taxes	2,277	2,389
Other long-term liabilities	34,603	32,569
Commitments and contingencies
Stockholders' equity (deficit)
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,844,174,521 shares issued as of June 30, 2026 and 1,838,678,628 as of December 31, 2025	18	18
Common stock held in treasury, at cost, 77,105,240 shares as of June 30, 2026 and 70,802,593 as of December 31, 2025	(10,618)	(9,146)
Additional paid-in capital	23,156	22,495
Accumulated deficit	(17,333)	(15,493)
Accumulated other comprehensive loss	(1,158)	(1,144)
Total stockholders' deficit	(5,935)	(3,270)
Noncontrolling interest	47	42
Total deficit	(5,888)	(3,228)
Total liabilities and equity (deficit)	$ 135,115	$ 133,960